Examination on the Acceptability, Feasibility and Effectiveness of a Digital Cognitive Training Software in Patients With Stable Schizophrenia in China

在中国对一款数字认知训练软件在稳定期精神分裂症患者中的可接受性、可行性和有效性进行研究

阅读:1

Abstract

OBJECTIVE: This single-arm study aimed to explore the acceptability and effectiveness of a digital cognitive training software (IBT-004) in patients with stable schizophrenia. METHODS: This study conducted an 8-week home-based cognitive training program, IBT-004, for patients with stable schizophrenia. Forty-seven participants were recruited from Peking University Sixth Hospital and Hebei Provincial Mental Health Center. IBT-004 focused on improving cognitive function through independent tasks. Cognitive function was assessed using the Chinese Brief Neurocognitive Suite of Tests (C-BCT) and self-report scales, with additional evaluation of the program's acceptability and feasibility. RESULTS: After 8 weeks of cognitive training, patients showed significant improvements in total cognitive scores, Digit Span, and Trial Making Test (P < 0.05). Subjective cognitive distress significantly decreased (Z = -3.758, P < 0.001). Age (B = -0.532, β = -0.476, P < 0.05) and training duration (B = 0.273, β = 0.340, P < 0.05) were significant predictors of Continuous Performance Test scores (F = 3.884, P < 0.05). Patients showed high acceptance of the software. Enjoyment scores (1-5 scale) ranged from 3.46 to 4.14, and difficulty scores (1-5 scale) ranged from 2.31 to 2.86, with no significant changes over time (P < 0.05). The average training time was 36.89 hours, and adherence reached 92.24%, indicating strong engagement and compliance. CONCLUSION: This study showed that a home-based online cognitive training program improved cognitive function in patients with stable schizophrenia. Significant gains were seen in overall cognitive scores, processing speed, and attention. Participants also reported reduced cognitive distress. Younger age and longer training hours were linked to better outcomes. The program had high adherence, supported by personalized adjustments and engaging features. These results confirm the program's feasibility and effectiveness for cognitive improvement in schizophrenia. CLINICAL TRIALS REGISTRATION: ChiCTR2200055930.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。